Cargando…
Antibody Conjugated PLGA Nanocarriers and Superparmagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma
Anti-CD133 monoclonal antibody (Ab)-conjugated poly(lactide-co-glycolide) (PLGA) nanocarriers, for the targeted delivery of oxaliplatin (OXA) and superparamagnetic nanoparticles (IO-OA) to colorectal cancer cells (CaCo-2), were designed, synthesized, characterized, and evaluated in this study. The c...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835878/ https://www.ncbi.nlm.nih.gov/pubmed/35163122 http://dx.doi.org/10.3390/ijms23031200 |
_version_ | 1784649540615274496 |
---|---|
author | Zumaya, Alma Lucia Villela Rimpelová, Silvie Štějdířová, Markéta Ulbrich, Pavel Vilčáková, Jarmila Hassouna, Fatima |
author_facet | Zumaya, Alma Lucia Villela Rimpelová, Silvie Štějdířová, Markéta Ulbrich, Pavel Vilčáková, Jarmila Hassouna, Fatima |
author_sort | Zumaya, Alma Lucia Villela |
collection | PubMed |
description | Anti-CD133 monoclonal antibody (Ab)-conjugated poly(lactide-co-glycolide) (PLGA) nanocarriers, for the targeted delivery of oxaliplatin (OXA) and superparamagnetic nanoparticles (IO-OA) to colorectal cancer cells (CaCo-2), were designed, synthesized, characterized, and evaluated in this study. The co-encapsulation of OXA and IO-OA was achieved in two types of polymeric carriers, namely, PLGA and poly(lactide-co-glycolide)-poly(ethylene glycol) (PLGA-PEG) by double emulsion. PLGA_IO-OA_OXA and PEGylated PLGA_IO-OA_OXA nanoparticles displayed a comparable mean diameter of 207 ± 70 nm and 185 ± 119 nm, respectively. The concentration of the released OXA from the PEGylated PLGA_IO-OA_OXA increased very rapidly, reaching ~100% release after only 2 h, while the PLGA_IO-OA_OXA displayed a slower and sustained drug release. Therefore, for a controlled OXA release, non-PEGylated PLGA nanoparticles were more convenient. Interestingly, preservation of the superparamagnetic behavior of the IO-OA, without magnetic hysteresis all along the dissolution process, was observed. The non-PEGylated nanoparticles (PLGA_OXA, PLGA_IO-OA_OXA) were selected for the anti-CD133 Ab conjugation. The affinity of Ab-coated nanoparticles for CD133-positive cells was examined using fluorescence microscopy in CaCo-2 cells, which was followed by a viability assay. |
format | Online Article Text |
id | pubmed-8835878 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88358782022-02-12 Antibody Conjugated PLGA Nanocarriers and Superparmagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma Zumaya, Alma Lucia Villela Rimpelová, Silvie Štějdířová, Markéta Ulbrich, Pavel Vilčáková, Jarmila Hassouna, Fatima Int J Mol Sci Article Anti-CD133 monoclonal antibody (Ab)-conjugated poly(lactide-co-glycolide) (PLGA) nanocarriers, for the targeted delivery of oxaliplatin (OXA) and superparamagnetic nanoparticles (IO-OA) to colorectal cancer cells (CaCo-2), were designed, synthesized, characterized, and evaluated in this study. The co-encapsulation of OXA and IO-OA was achieved in two types of polymeric carriers, namely, PLGA and poly(lactide-co-glycolide)-poly(ethylene glycol) (PLGA-PEG) by double emulsion. PLGA_IO-OA_OXA and PEGylated PLGA_IO-OA_OXA nanoparticles displayed a comparable mean diameter of 207 ± 70 nm and 185 ± 119 nm, respectively. The concentration of the released OXA from the PEGylated PLGA_IO-OA_OXA increased very rapidly, reaching ~100% release after only 2 h, while the PLGA_IO-OA_OXA displayed a slower and sustained drug release. Therefore, for a controlled OXA release, non-PEGylated PLGA nanoparticles were more convenient. Interestingly, preservation of the superparamagnetic behavior of the IO-OA, without magnetic hysteresis all along the dissolution process, was observed. The non-PEGylated nanoparticles (PLGA_OXA, PLGA_IO-OA_OXA) were selected for the anti-CD133 Ab conjugation. The affinity of Ab-coated nanoparticles for CD133-positive cells was examined using fluorescence microscopy in CaCo-2 cells, which was followed by a viability assay. MDPI 2022-01-21 /pmc/articles/PMC8835878/ /pubmed/35163122 http://dx.doi.org/10.3390/ijms23031200 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zumaya, Alma Lucia Villela Rimpelová, Silvie Štějdířová, Markéta Ulbrich, Pavel Vilčáková, Jarmila Hassouna, Fatima Antibody Conjugated PLGA Nanocarriers and Superparmagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma |
title | Antibody Conjugated PLGA Nanocarriers and Superparmagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma |
title_full | Antibody Conjugated PLGA Nanocarriers and Superparmagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma |
title_fullStr | Antibody Conjugated PLGA Nanocarriers and Superparmagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma |
title_full_unstemmed | Antibody Conjugated PLGA Nanocarriers and Superparmagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma |
title_short | Antibody Conjugated PLGA Nanocarriers and Superparmagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma |
title_sort | antibody conjugated plga nanocarriers and superparmagnetic nanoparticles for targeted delivery of oxaliplatin to cells from colorectal carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835878/ https://www.ncbi.nlm.nih.gov/pubmed/35163122 http://dx.doi.org/10.3390/ijms23031200 |
work_keys_str_mv | AT zumayaalmaluciavillela antibodyconjugatedplgananocarriersandsuperparmagneticnanoparticlesfortargeteddeliveryofoxaliplatintocellsfromcolorectalcarcinoma AT rimpelovasilvie antibodyconjugatedplgananocarriersandsuperparmagneticnanoparticlesfortargeteddeliveryofoxaliplatintocellsfromcolorectalcarcinoma AT stejdirovamarketa antibodyconjugatedplgananocarriersandsuperparmagneticnanoparticlesfortargeteddeliveryofoxaliplatintocellsfromcolorectalcarcinoma AT ulbrichpavel antibodyconjugatedplgananocarriersandsuperparmagneticnanoparticlesfortargeteddeliveryofoxaliplatintocellsfromcolorectalcarcinoma AT vilcakovajarmila antibodyconjugatedplgananocarriersandsuperparmagneticnanoparticlesfortargeteddeliveryofoxaliplatintocellsfromcolorectalcarcinoma AT hassounafatima antibodyconjugatedplgananocarriersandsuperparmagneticnanoparticlesfortargeteddeliveryofoxaliplatintocellsfromcolorectalcarcinoma |